CHMFL-FLT3-165

N/A

Report date: 2022/12/06 17:19:36
NME

Base Information

Drug NameCHMFL-FLT3-165
Drug Alias NameCHMFL-FLT3-165
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase receptor FLT3 inhibitors
TargetsTyrosine-protein kinase receptor FLT3
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHefei Cosource Medicine TechnologyHefei Academy Of Physical Sciences, Chinese Academy Of Sciences
China Registration ClassN/A

Develop Information

Active CompaniesHefei Academy Of Physical Sciences, Chinese Academy Of SciencesHefei Cosource Medicine Technology
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A